Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Scinnohub Pharmaceutical Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the count of pending actions matches the count of examiners, suggesting that the company's current prosecution workload is not concentrated under any individual.
BAUER, BRIANNA LEE is identified as the busiest examiner for the portfolio, currently handling 1 pending action. This 1 action is part of the total 2 pending office actions for the company. The involvement of 2 distinct art units for the actions indicates that the technical subject matter, while categorized under Biotechnology & Pharmaceuticals, is reviewed by different specialized groups within the patent office.
For practitioners, this spread across distinct art units means that prosecution strategies may need to account for the specific tendencies of different examination environments. With distinct examiners involved, the company maintains a small footprint across the office's personnel. The presence of a pending action with the busiest examiner highlights a balanced distribution where no examiner is managing more than a single case for this entity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833217 | COMPOUND FOR REGULATING AND CONTROLLING 15-PGDH ACTIVITY AND PREPARATION METHOD THEREFOR | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18856225 | COMPOUND CAPABLE OF REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH, AND PREPARATION METHOD THEREFOR | BAUER, BRIANNA LEE | 1623 | §112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18833217 | COMPOUND FOR REGULATING AND CONTROLLING 15-PGDH ACTIVITY AND PREPARATION METHOD THEREFOR | RICCI, CRAIG D | 1611 | §103DP | Non-Final OA | — | Pending | Jul 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScinnohub Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brianna Lee Bauer has the most, with 1 of Scinnohub Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
